{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5fa6e85678bc150948ccfeb4/5fa6e85d4a2a5c52d1e331bd?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Treating HCV in PWID: Best Practices","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5fa6e85678bc150948ccfeb4/1607723671162-ac20001d781cf59bcd82fc8a7c71d51a.jpeg?height=200","description":"<p>Take our <a href=\"https://elit.dkbmed.com/issues/60/test\">post-test</a> to claim CME credits. \n\n</p><p>To read a companion newsletter&nbsp;<a href=\"https://elit.dkbmed.com/issues/60\">click here</a>.\n\n</p><p>Hepatitis C has become “curable” for &gt;90% of those infected.&nbsp;But while&nbsp;universal&nbsp;HCV elimination&nbsp;is medically possible,&nbsp;this goal is compromised by&nbsp;certain populations&nbsp;who remain&nbsp;underscreened, undertreated, and underserved and continue to spread&nbsp;the virus. One such population is people who inject drugs&nbsp;(PWID).&nbsp;&nbsp;&nbsp;</p><p>\n</p><p>In this issue,&nbsp;Dr.&nbsp;Brianna Norton&nbsp;and Dr.&nbsp;Matthew Akiyama&nbsp;from&nbsp;the&nbsp;Albert Einstein College of Medicine&nbsp;analyze the most important data to explain how substance use impacts&nbsp;adherence and the risk of&nbsp;HCV&nbsp;reinfection.</p>","author_name":"eViralHepatitis Review"}